This company has been marked as potentially delisted and may not be actively trading.

Abcam (ABCM) Competitors

ABCM vs. DFTX, HYPD, LIAN, PHXM, and ADIL

Should you be buying Abcam stock or one of its competitors? The main competitors of Abcam include Definium Therapeutics (DFTX), Hyperion DeFi (HYPD), LianBio (LIAN), PHAXIAM Therapeutics (PHXM), and Adial Pharmaceuticals (ADIL). These companies are all part of the "biotechnology" industry.

How does Abcam compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

: Abcam has higher revenue and earnings than Definium Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Definium Therapeutics N/A N/A -$183.79M -$2.13 N/A
Abcam $379.70M 14.49 -$10.51M N/A N/A
: 27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 90.4% of Abcam shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Abcam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Abcam's return on equity of 0.00% beat Definium Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Definium Therapeutics N/A -82.07% -58.73%
Abcam N/A N/A N/A
: In the previous week, Definium Therapeutics had 3 more articles in the media than Abcam. MarketBeat recorded 3 mentions for Definium Therapeutics and 0 mentions for Abcam. Definium Therapeutics' average media sentiment score of 0.64 beat Abcam's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Definium Therapeutics Positive
Abcam Neutral
: Definium Therapeutics currently has a consensus price target of $38.00, indicating a potential upside of 62.95%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Definium Therapeutics is more favorable than Abcam.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)

11 Buy rating(s)

3 Strong Buy rating(s)
3.07
Abcam
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Definium Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Abcam has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.13	N/A
Abcam	$379.70M	14.49	-$10.51M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-82.07%	-58.73%
Abcam	N/A	N/A	N/A

Company	Overall Sentiment
Definium Therapeutics	Positive
Abcam	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	3.07
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Definium Therapeutics beats Abcam on 7 of the 13 factors compared between the two stocks.

How does Abcam compare to Hyperion DeFi?

Abcam (NASDAQ:ABCM) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

: Hyperion DeFi has a consensus price target of $5.88, indicating a potential upside of 59.65%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than Abcam.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abcam
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Hyperion DeFi
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.25
: Abcam has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500.
: Abcam's return on equity of 0.00% beat Hyperion DeFi's return on equity.
Company Net Margins Return on Equity Return on Assets
Abcam N/A N/A N/A
Hyperion DeFi N/A -129.97% -92.39%
: Abcam has higher revenue and earnings than Hyperion DeFi.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abcam $379.70M 14.49 -$10.51M N/A N/A
Hyperion DeFi $810K 51.75 -$45.31M -$11.80 N/A
: 90.4% of Abcam shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 6.7% of Abcam shares are owned by insiders. Comparatively, 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: In the previous week, Hyperion DeFi had 5 more articles in the media than Abcam. MarketBeat recorded 5 mentions for Hyperion DeFi and 0 mentions for Abcam. Hyperion DeFi's average media sentiment score of 0.40 beat Abcam's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Company Overall Sentiment
Abcam Neutral
Hyperion DeFi Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Hyperion DeFi	N/A	-129.97%	-92.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	$379.70M	14.49	-$10.51M	N/A	N/A
Hyperion DeFi	$810K	51.75	-$45.31M	-$11.80	N/A

Company	Overall Sentiment
Abcam	Neutral
Hyperion DeFi	Neutral

Summary

Hyperion DeFi beats Abcam on 9 of the 14 factors compared between the two stocks.

How does Abcam compare to LianBio?

Abcam (NASDAQ:ABCM) and LianBio (NASDAQ:LIAN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

: 90.4% of Abcam shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 6.7% of Abcam shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Abcam has higher revenue and earnings than LianBio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abcam $379.70M 14.49 -$10.51M N/A N/A
LianBio N/A N/A -$110.29M -$0.81 N/A
: Abcam's return on equity of 0.00% beat LianBio's return on equity.
Company Net Margins Return on Equity Return on Assets
Abcam N/A N/A N/A
LianBio N/A -33.17% -30.19%
: Abcam has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
: In the previous week, Abcam's average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.
Company Overall Sentiment
Abcam Neutral
LianBio Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	$379.70M	14.49	-$10.51M	N/A	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

Company	Overall Sentiment
Abcam	Neutral
LianBio	Neutral

Summary

Abcam beats LianBio on 6 of the 7 factors compared between the two stocks.

How does Abcam compare to PHAXIAM Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

: PHAXIAM Therapeutics has higher earnings, but lower revenue than Abcam.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PHAXIAM Therapeutics N/A N/A -$240K N/A N/A
Abcam $379.70M 14.49 -$10.51M N/A N/A
: PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Abcam has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
: 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 90.4% of Abcam shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 6.7% of Abcam shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
PHAXIAM Therapeutics N/A N/A N/A
Abcam N/A N/A N/A
: In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.
Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Abcam Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Abcam	$379.70M	14.49	-$10.51M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Abcam	N/A	N/A	N/A

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Abcam	Neutral

Summary

Abcam beats PHAXIAM Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Abcam compare to Adial Pharmaceuticals?

Abcam (NASDAQ:ABCM) and Adial Pharmaceuticals (NASDAQ:ADIL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

: In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Abcam. Abcam's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Abcam Neutral
Adial Pharmaceuticals Neutral
: 90.4% of Abcam shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 6.7% of Abcam shares are owned by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Abcam's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Abcam N/A N/A N/A
Adial Pharmaceuticals N/A -182.34% -141.27%
: Adial Pharmaceuticals has lower revenue, but higher earnings than Abcam.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abcam $379.70M 14.49 -$10.51M N/A N/A
Adial Pharmaceuticals N/A N/A -$7.98M -$18.75 N/A
: Adial Pharmaceuticals has a consensus target price of $22.75, suggesting a potential upside of 1,349.97%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Abcam.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abcam
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Adial Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Abcam has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Company	Overall Sentiment
Abcam	Neutral
Adial Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Abcam	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-182.34%	-141.27%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abcam	$379.70M	14.49	-$10.51M	N/A	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$18.75	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Adial Pharmaceuticals beats Abcam on 6 of the 11 factors compared between the two stocks.

Get Abcam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCM vs. The Competition

Export

Metric	Abcam	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.50B	$459.30M	$6.26B	$12.19B
Dividend Yield	N/A	3.86%	2.74%	5.26%
P/E Ratio	N/A	4.18	28.64	27.41
Price / Sales	14.49	7,147.12	530.16	85.10
Price / Cash	40.17	13.13	43.35	54.56
Price / Book	6.12	82.30	9.98	6.87
Net Income	-$10.51M	-$96.07M	$3.54B	$332.68M

Abcam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCM Abcam	N/A	$23.99 flat	N/A	N/A	$5.50B	$379.70M	N/A	1,760
DFTX Definium Therapeutics	3.6552 of 5 stars	$21.88 +6.8%	$38.00 +73.7%	+270.9%	$2.04B	N/A	N/A	40
HYPD Hyperion DeFi	2.9278 of 5 stars	$4.03 +1.8%	$5.88 +45.8%	+251.0%	$45.11M	$810K	N/A	40	News Coverage
LIAN LianBio	N/A	$0.12 flat	N/A	-30.0%	$13.18M	N/A	N/A	110
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCM) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abcam (ABCM) Competitors

ABCM vs. DFTX, HYPD, LIAN, PHXM, and ADIL

How does Abcam compare to Definium Therapeutics?

Summary

How does Abcam compare to Hyperion DeFi?

Summary

How does Abcam compare to LianBio?

Summary

How does Abcam compare to PHAXIAM Therapeutics?

Summary

How does Abcam compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCM vs. The Competition

Abcam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abcam (ABCM) Competitors

ABCM vs. DFTX, HYPD, LIAN, PHXM, and ADIL

How does Abcam compare to Definium Therapeutics?

Summary

How does Abcam compare to Hyperion DeFi?

Summary

How does Abcam compare to LianBio?

Summary

How does Abcam compare to PHAXIAM Therapeutics?

Summary

How does Abcam compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCM vs. The Competition

Abcam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools